SpliceBio vs Andson Biotech
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $135M Series B led by Sanofi Ventures and EQT (Jun 2025). First patient dosed in Phase 1/2 for Stargardt disease (Jan 2026). Overcomes 4.7kb AAV cargo limit.
About
SpliceBio is a gene therapy company whose protein trans-splicing platform overcomes the 4.7-kilobase cargo limit of adeno-associated viral (AAV) vectors — the primary delivery vehicle for gene therapy — unlocking treatments for large-gene diseases previously untreatable. The company raised $135 million in Series B financing co-led by Sanofi Ventures and EQT Life Sciences in June 2025, and dosed its first patient in Phase 1/2 Part B for SB-007 in Stargardt disease in January 2026.
Mass spectrometry sample prep and data science platform delivering 100x productivity for biopharma protein analysis; $9.1M from Merck Digital Sciences Studio, NIH, and YC at $1.8M revenue.
About
Andson Biotech is an Atlanta-based healthcare technology company providing mass spectrometry solutions for biopharma and biomanufacturing — offering the DynaCHIP hardware system (a novel mass spectrometry sample preparation platform) and DynaMARK data science module that together deliver up to 100x productivity improvements in protein and biomolecule analysis workflows compared to conventional mass spectrometry setups. Backed by Y Combinator, Merck Digital Sciences Studio, and NIH with $9.1 million raised, Andson achieved $1.8 million in revenue as of December 2024.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.